zip >>> 02451
sector >>> Healthcare
fullTimeEmployees >>> 75
longBusinessSummary >>> ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
city >>> Waltham
phone >>> 781 895 0600
state >>> MA
country >>> United States
companyOfficers >>> []
website >>> http://www.immunogen.com
maxAge >>> 1
address1 >>> 830 Winter Street
industry >>> Biotechnology
previousClose >>> 3.5
regularMarketOpen >>> 3.51
twoHundredDayAverage >>> 4.0291367
trailingAnnualDividendYield >>> None
payoutRatio >>> 0
volume24Hr >>> None
regularMarketDayHigh >>> 3.7
navPrice >>> None
averageDailyVolume10Day >>> 2193528
totalAssets >>> None
regularMarketPreviousClose >>> 3.5
fiftyDayAverage >>> 3.7826471
trailingAnnualDividendRate >>> None
open >>> 3.51
toCurrency >>> None
averageVolume10days >>> 2193528
expireDate >>> None
yield >>> None
algorithm >>> None
dividendRate >>> None
exDividendDate >>> None
beta >>> 2.148829
circulatingSupply >>> None
startDate >>> None
regularMarketDayLow >>> 3.48
priceHint >>> 4
currency >>> USD
regularMarketVolume >>> 1186475
lastMarket >>> None
maxSupply >>> None
openInterest >>> None
marketCap >>> 642314560
volumeAllCurrencies >>> None
strikePrice >>> None
averageVolume >>> 2166231
priceToSalesTrailing12Months >>> 7.429295
dayLow >>> 3.48
ask >>> 3.68
ytdReturn >>> None
askSize >>> 3000
volume >>> 1186475
fiftyTwoWeekHigh >>> 7.07
forwardPE >>> -4.9066668
fromCurrency >>> None
fiveYearAvgDividendYield >>> None
fiftyTwoWeekLow >>> 1.95
bid >>> 3.57
tradeable >>> False
dividendYield >>> None
bidSize >>> 3100
dayHigh >>> 3.7
exchange >>> NMS
shortName >>> ImmunoGen, Inc.
longName >>> ImmunoGen, Inc.
exchangeTimezoneName >>> America/New_York
exchangeTimezoneShortName >>> EDT
isEsgPopulated >>> False
gmtOffSetMilliseconds >>> -14400000
quoteType >>> EQUITY
symbol >>> IMGN
messageBoardId >>> finmb_29794
market >>> us_market
annualHoldingsTurnover >>> None
enterpriseToRevenue >>> 5.184
beta3Year >>> None
profitMargins >>> -0.81338
enterpriseToEbitda >>> -9.755
52WeekChange >>> 0.5206611
morningStarRiskRating >>> None
forwardEps >>> -0.75
revenueQuarterlyGrowth >>> None
sharesOutstanding >>> 174542000
fundInceptionDate >>> None
annualReportExpenseRatio >>> None
bookValue >>> -0.141
sharesShort >>> 17472965
sharesPercentSharesOut >>> 0.1001
fundFamily >>> None
lastFiscalYearEnd >>> 1577750400
heldPercentInstitutions >>> 0.76608
netIncomeToCommon >>> -70322000
trailingEps >>> -0.44
lastDividendValue >>> None
SandP52WeekChange >>> 0.108078
priceToBook >>> None
heldPercentInsiders >>> 0.01115
nextFiscalYearEnd >>> 1640908800
mostRecentQuarter >>> 1593475200
shortRatio >>> 9
sharesShortPreviousMonthDate >>> 1596153600
floatShares >>> 151577609
enterpriseValue >>> 448227968
threeYearAverageReturn >>> None
lastSplitDate >>> None
lastSplitFactor >>> None
legalType >>> None
morningStarOverallRating >>> None
earningsQuarterlyGrowth >>> None
dateShortInterest >>> 1598832000
pegRatio >>> None
lastCapGain >>> None
shortPercentOfFloat >>> 0.11229999
sharesShortPriorMonth >>> 17772471
category >>> None
fiveYearAverageReturn >>> None
regularMarketPrice >>> 3.51
logo_url >>> https://logo.clearbit.com/immunogen.com
